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There has been a resurgence of interest in cancer metabolism; primarily in the
resetting of metabolism within malignant cells. Metabolism within cells has always
been a tightly regulated process; initially in protozoans due to metabolic enzymes,
and the intracellular signaling pathways that regulate these, being directly sensitive to
the availability of nutrients. With the evolution of metazoans many of these controls
had been overlaid by extra-cellular regulators that ensured coordinated regulation of
metabolism within the community of cells that comprised the organism. Central to these
systemic regulators is the insulin/insulin-like growth factor (IGF) system that throughout
evolution has integrated the control of tissue growth with metabolic status. Oncological
interest in the main systemic metabolic regulators greatly subsided when pharmaceutical
strategies designed to treat cancers failed in the clinic. During the same period,
however the explosion of new information from genetics has revealed the complexity
and heterogeneity of advanced cancers and helped explain the problems of managing
cancer when it reaches such a stage. Evidence has also accumulated implying that the
setting of the internal environment determines whether cancers progress to advanced
disease and metabolic status is clearly an important component of this local ecology. We
are in the midst of an epidemic of metabolic disorders and there is considerable research
into strategies for controlling metabolism. Integrating these new streams of information
suggests new possibilities for cancer prevention; both primary and secondary.
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INTRODUCTION
The revolution in genetics has led to considerable advances in our understanding of the complexity
and plasticity of clinical cancers: providing new insight into the problems of treating advanced
cancers (1). A realization of the major challenges facing current treatment strategies for the medical
management of advanced disease has reinvigorated attention on prevention. With the gradual
decline in tobacco usage across North America and Western Europe surveys of public health
trends predict that smoking as the leading modifiable cause of cancer will soon be overtaken by
metabolic-imbalance, caused by overconsumption of calories and lack of physical activity and with
the obvious clinical sequelae of obesity and type 2 diabetes (2). This has accelerated interest in the
role that keymetabolic regulators play in cancer. Considerable experimental work in cell and animal
models indicated that the insulin/IGF system has important effects on cancer; this converged with
evidence from population epidemiology such that by the turn of the century virtually the whole
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pharmaceutical industry was developing anti-cancer drugs
targeting this system (3). Over the subsequent years this
excitement has largely waned as each company introduced drugs
into clinical trials with disappointing results and subsequent
withdrawal. However, over the same period the explosion of
information from cancer genetics has changed our understanding
of cancer etiology and this review aims to revisit the potential
role of metabolic regulation and insulin/IGFs in the common
epithelial cancers in the light of this new understanding. Firstly,
we will describe the insulin/IGF system and how it has evolved
in a pivotal role for the integration of tissue growth with
metabolic status. Their well-established role in synchronizing
metabolic regulation according to nutritional status will be
briefly discussed in relation to its relevance to cancers. The
evidence linking insulin/IGFs with cancer has been extensively
reviewed elsewhere in recent years (4–6) and therefore we will
limit the discussion here to a few comments. We will then
outline how the flaws in the prevailing genetic paradigm for
cancer etiology have been exposed by recent findings and how
this should alter our perceptions of the actual events that
determine the course of these cancers. This will then set the
context of how, and at what stage, metabolic status and its
regulators, including insulin/IGFs, may be affecting the course
of carcinogenesis.
The evidence linking metabolic disturbance (and
insulin/IGFs) with cancer added to the shift toward considering
prevention as a viable option. At the same time evidence was
emerging indicating that by the time cancers were clinically
evident the heterogeneity and plasticity within the tumors was so
complex that it presented considerable challenges to treatment.
This stirred many leading cancer researchers to consider that it
was timely for a redirection of efforts away from cures and more
toward prevention (1). It now seems a little incongruous that
so much effort was then directed toward developing treatments
targeting the IGF-system that were then tested in clinical trials
in patients with advanced cancer. At the time however it was
a popular strategy within the pharmaceutical industry and it
built on some early successes in targeting other growth factors.
It should however be noted that no other targeted therapy has
ever worked for any cancer when applied to all patients, without
some form of patient selection, usually based on biomarkers
that indicated a responsive subpopulation. In the absence
of proven markers of therapeutic response, agents targeting
the IGF-system have thus far only been tested in unselected
patients (5, 7). With hindsight this was a mistake and the poor
results could maybe have been predicted. We will then end by
discussing how we should move beyond these disappointments
with some thoughts on the potential of where research into
the insulin/IGF-system may impact on future strategies to
combat cancer.
THE INSULIN/IGF SYSTEM
The insulin/IGFs form part of a fundamental regulatory system
that comprises four secreted peptides; two with very restricted
expression that are just secreted from specialist endocrine
cells in the pancreas, proinsulin and insulin, and two more
general signals secreted from most cells throughout the body,
IGF-I, and IGF-II. These peptides are very homologous and
originated by gene duplications and indeed the IGF-II gene is
adjacent to the insulin gene. The peptides also share considerable
functional homology. It is often forgotten that in addition to
being discovered as growth factors that mediate the effects
of growth hormone (GH) (8) they were also independently
discovered as non-suppressible insulin-like activity (NSILA),
distinguishable from actual insulin by specific antibodies; indeed
in some bioassays insulin itself accounted for <10% of the
metabolic insulin-activity present in normal human serum (9).
Following the structural characterization of these peptides it
was realized that IGF-II was responsible for the majority of
this metabolic “insulin-like” activity present in serum. In light
of the similarity between these peptides, both structurally and
functionally, their physiology has to be interpreted with an
understanding of their relative abundance throughout the body:
with IGF-II levels normally being 3- to 4-fold higher than that
of IGF-I and around 1,000-fold higher than that of insulin
(10). When considering the role of IGFs in cancer, the main
focus is generally on their activity in promoting cell growth and
survival and their major contribution to metabolic regulation is
generally overlooked.
These ligands regulate cell functions via activation of
classical tyrosine kinase cell surface receptors that, as with
the ligands, share similar homology both structurally and
functionally (11) (Figure 1). The IGF-I and insulin receptors are
all heterotetramers: both genes are translated and the mature
protein is cleaved to yield an extracellular α-subunit and a
disulphide-linked transmembrane β-subunit and these dimerise
to form the tetramer. The IGF-IR binds IGF-I and IGF-II
with high affinity and has little affinity for insulin. The insulin
receptor exists as two isoforms, due to alternative mRNA splicing
with the IR-A isoform containing 12 fewer amino acids in
the extracellular C-terminal domain of the α-subunit due to
splicing out of exon 11 whereas the IR-B isoform has these
additional amino acids due to exon 11 being spliced in. These
extracellular α-subunits form the ligand binding domain. While
the IR-B predominantly binds insulin and has a much lower
affinity for IGF-I/-II and hence is the classic insulin receptor;
the loss of 12 amino from IR-A diminishes this specificity and
results in a relative increase in affinity for IGF-II (12). As a
consequence IGF-II binds IR-A with an affinity approaching that
of insulin, and IR-A also binds proinsulin with high affinity, in
contrast to the very low affinity for these ligands with IR-B (12).
Although IR-A binds insulin and IGF-II with similar affinities
there is evidence that these ligands induce differential signaling
and effects (13, 14). This has important pathophysiological
implications, especially in view of the marked differences in
abundance of these ligands. The α-/β- dimers of the insulin
and IGF-IR are so similar that they hetero-dimerise to form
hybrid receptors, both IR-A/IGF-IR hybrids and IR-B/IGF-IR
hybrids, depending on the relative expression of each receptor in
a particular cell. These hybrid receptors appear to predominantly
act as IGF-I receptors (15, 16), but their pathophysiology is still
poorly understood.
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FIGURE 1 | Overview of the IGF system. In the body the IGFs are constantly present at very high levels due to their binding to the IGFBPs, with IGF-II levels 3 to 4-fold
higher than IGF-I. Following meals insulin is secreted from the pancreas but is the rapidly cleared, resulting in episodic transient exposure to the tissues. At the cellular
level these ligands interact with a family of signaling tyrosine kinase receptors: the IGF-IR and the insulin receptor, which exists in two alternatively spliced isoforms.
The IRB predominantly only binds insulin whereas the IRA also binds IGF-II, which due to its abundance is the most likely ligand. These receptors initiate intracellular
signaling, principally the PI3K/Akt and Ras/Raf/MAP kinase pathways, that set in train processes that culminate in increased cell proliferation, survival and metabolism.
In addition to maintaining levels of IGFs and restricting their interaction with cell surface receptors; the IGFBPs also have independent actions. Via interaction with
integrin receptors IGFBP-2 suppresses PTEN, the phosphatase that counteracts the activity of PI3K and therefore IGFBP-2 can release the brake on IGF signaling. In
addition to IGFBPs controlling the availability of IGFs there is also a cell surface IGF-IIR that limits the availability of IGF-II by targeting it for lysosomal degradation.
There is also an IGF-II receptor (IGF-IIR) that is completely
unrelated and is structurally and functionally different from
the other IGF receptors and is a single large transmembrane
protein (17, 18) The IGF-II receptor binds IGF-II with very
high affinity and has very little affinity for IGF-I or insulin
but is generally considered to not act as a traditional signaling
receptor in response to IGF-II binding. It is thought to act as a
clearance receptor for IGF-II controlling cell exposure to IGF-II,
internalizing and directing IGF-II to lysosomes for degradation;
since disruption of gene expression in mice resulted in elevated
IGF-II levels and overgrowth (19). The cellular location of the
IGF-IIR is dynamically regulated by insulin in the same way
as the glucose transporter, Glut 4 (20–22); these receptors are
mainly intracellular but are rapidly translocated to the cell surface
in response to insulin. This dynamic translocation of these
receptors has been known for over 30 years and although still
poorly understood it could, like the dynamic translocation of
Glut4, potentially represent a novel means for metabolic control,
although direct evidence for this has yet to be demonstrated.
When nutrient abundance triggers pancreatic insulin release, the
insulin could result in internalization of the IGF-IIR that could
then lead to more IGF-II interacting with the IGF-IR and the IR-
A complimenting the direct actions of insulin itself; however this
is yet to be proven experimentally. These IGF-II receptors are in
addition, clearly multifunctional: their most well characterized
role is as mannose 6-phosphate receptors involved in the
targeting of lysosomal enzymes to the lysosomes within the cell.
These receptors however, also bind latent transforming growth
factor-β (TGF-β) and enable its activation on the cell surface.
They also bind to retinoids, urokinase-receptors, and many other
proteins. As TGF-β has many important effects on cancers,
particularly in relation to differentiation status and stimulating
epithelial to mesenchymal transition (EMT) this interaction
may have potential implications for interactions between the
insulin/IGF-system and these other regulatory pathways. The
functional consequences of interactions between IGF-II and the
other possible ligands of the IGF-II receptor are far from clear
(17, 18, 23).
INSULIN AND IGF: SIMILAR BUT VERY
DIFFERENT REGULATORY SYSTEMS
Insulin, the IGFs and their receptors clearly evolved from early
gene-duplication events; yet despite their structural similarities
and the similarities of their cellular activity, they have evolved to
operate as very different regulatory systems. Insulin is a classical
endocrine regulator; its expression is very restricted, principally
just to the beta-cells of the pancreatic islets where there are
intracellular stores in secretory granules and it is secreted via the
regulated secretory pathway in response to stimuli, principally
glucose fluctuations that enables an acute regulation of metabolic
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activity. Insulin is secreted in an episodic manner from the
pancreas into the circulation; blood levels therefore fluctuate
widely, and it is transported in the blood to target tissues where
it activates cell receptors. In contrast the IGFs are expressed
in most cell types in tissues throughout the body and they are
secreted via the constitutive secretory pathway: they are not
stored in intracellular secretory granules, but they are secreted
immediately, as soon as they are produced (10). Although
there are no intracellular stores of IGFs a sophisticated system
has evolved for maintaining extracellular reservoirs of IGFs
formed due to their association with very specific high affinity
binding proteins.
In humans there are 6 binding proteins (IGFBP-1 to −6) that
bind IGFs with high affinity but do not bind insulin; these are
unrelated to the cell-surface receptors but are structurally very
closely related to each other (24). The six IGFBPs all have very
distinct functional properties and they are produced in different
quantities and combinations in different tissues (24). The IGFBPs
sequester the IGFs as they are secreted and considerably slow
their clearance; enabling very high concentrations of IGFs to
build-up. In the circulation two of the IGFBPs, IGFBP-3, and
IGFBP-5 are bound to a further large glycoprotein, the acid
labile subunit (ALS) that is present in excess. This ternary
complex is too large to cross capillaries and hence is retained
in the circulation and further slows clearance such that in
adult humans the total IGF-I and IGF-II concentration in the
circulation is around 100 nanomolar. This is around 1,000 times
higher concentration than that of insulin and while insulin
levels fluctuate acutely in response to metabolic requirements the
circulating levels of IGFs are very stable due to the very long
half-life of these complexes (10).
Although expressed in most tissues, the majority of the IGFs
present in the circulation originate from the liver where the
production of IGF-I and IGFBP-3 are regulated by GH but
are also very dependent on nutritional intake (25). The high,
stable levels of circulating IGFs therefore provide a large pool of
metabolic regulators that reflect chronic nutritional status. At the
cellular level, optimal activation of the insulin and IGF receptors
are both achieved with just 1–2 nanomolar concentrations,
indicating that there is a vast excess of IGFs in the circulation.
Hence while the activity of insulin throughout the body is largely
determined by the rate of secretion from the pancreas, in contrast
the constitutive secretion of the IGFs within any tissue is just
one of the determinants of the total amount of IGF that the
cells are exposed to and the control of activity is much more
complex (10, 24). The IGFs bind the IGFBPs with affinities
higher than that of the IGF-I receptor, so most of the IGF
in the body has restricted availability for receptor activation.
Activity in a tissue is therefore not necessarily determined by
secretion rate of IGFs and not necessarily determined by total IGF
concentration (10).
The IGFs are made available from the large soluble stores,
maintained due to their association with the high affinity IGFBPs,
in a controlled manner by different mechanisms that lower the
affinity of these interactions: shifting the equilibrium in favor of
IGFs binding to cellular receptors. In the circulation the majority
of IGF is associated with IGFBP-3 and the ALS. The ALS binds to
a C-terminal region of IGFBP-3 that also binds to proteoglycans
present on cell surfaces and in the extracellular matrix (ECM).
It is therefore possible that such proteoglycans on the surface of
endothelial cells compete for binding to IGFBP-3 and displace the
ALS generating a binary complex that can then perfuse across the
capillaries into the tissues (26). There is however an additional
more specific mechanism for controlling delivery of IGFs from
the IGFBP-maintained reservoirs. Each of the IGFBPs appears
to be subject to specific limited proteolysis (27). The proteolysis
of IGFBPs lowers the affinity with which they bind IGFs, not
always complete loss of binding, but even a small decrease in
affinity could result in a shift in the complex equilibrium that
must exist in vivo presumably making the IGFs more available
for cell receptors. This physiology has important implications for
cancers; tumors become life threatening when they invade and
spread around the body, processes that depend on proteolytic
degradation of the ECM. This can mobilize latent IGFs held with
soluble IGFBPs or IGFBPs that are sequestered onto the ECMdue
to binding to proteoglycans. In addition the same ECM proteases
can also act on the IGFBPs increasing the bio-availability of the
large latent reservoir of IGFs that they hold (24).
INTRACELLULAR SIGNALING AND
METABOLISM
The IR and the IGF-IR are members of the tyrosine kinase
family of cell surface receptors; several homologous members
of which are recognized to be oncogenes. Upon binding of
insulin/IGFs to the α-subunit there is a conformational change
resulting in activation of the tyrosine kinase activity within
the intracellular β-subunit that results in autophosphorylation
of several intracellular sites that then provide docking sites
for the recruitment of a variety of adaptor proteins including
the insulin receptor substrates (IRS-1 to−4), Shc and receptor
for activated C kinase 1 (RACK1). This then enables the
assembly of signaling complexes that activate networks of
signaling pathways. The two best characterized of these are
the PI3K/Akt/mTOR/S6K and Grb2/SOS/Ras/Raf/MAP kinase
pathways (28, 29) (Figure 1). Of particular interest in relation to
cancer metabolism is the PI3K pathway. In single cell organisms,
such as yeast, PI3K acts as a nutrient sensor and is directly
activated by the availability of amino acids with consequent
activation of mTOR/S6K (30). In higher multicellular animals
PI3K is not directly activated by nutrients but has evolved
into heterodimers comprising a p110 catalytic subunit and a
p85 regulatory subunit. In quiescent cells these dimers are
cytoplasmic and the p85 subunit represses the catalytic activity
of p110. Following activation of the IR or the IGF-IR these
dimers are recruited to the cell membrane by IRS-1 and IRS-
2 via SH2 domains in p85; the binding of which relieves the
repression of p110 activity (31). This evolved system enables
regulation according to nutrient availability to be integrated by
communal signals across communities of cells rather than being
controlled directly by nutrients at the individual cellular level,
thus ensuring that growth and metabolism are synchronized
within metazoans. The lipid kinase activity of PI3K, that recruits
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and activates Akt, is opposed by the lipid phosphatase PTEN
(phosphatase and tensin homolog), a tumor suppressor gene,
expression of which is commonly lost in many cancers (31).
Interestingly the p85 regulatory subunit of PI3K also binds to
PTEN resulting in enhanced phosphatase activity, in contrast
to its repression of PI3K activity (32). Thus, p85 can negatively
regulate the PI3K/Akt pathway by repressing p110 PI3K and
enhancing PTEN. An additional layer of metabolic control also
operates via IGFBP-2, itself metabolically regulated, which when
free from IGFs can interact with cell surface integrin receptors
and suppress PTEN activity (33). This appears to provide a
synchronized communal control of the PI3K/Akt pathway with
IGFs acting to apply the “accelerator” and IGFBP-2 also removing
the “brake.”
INSULIN/IGFS, NUTRITION, METABOLISM,
AND GROWTH
Early human development is tightly regulated by the insulin/IGF
axis (34), ensuring that growth and development only proceed
when the cells receive the appropriate signal indicating that
sufficient nutrients are available. In utero nutrients are supplied
constantly via the placenta and not via the gut. Pancreatic insulin
secretion is less dependent on acute variations in nutritional
intake and by far the most abundant ligand for insulin/IGF
receptors is IGF-II which appears to play an important role in
placental function and in the control of nutrient partitioning
(35). Both IGF-II and the IGF-II receptor are imprinted genes
and it has been proposed that this has evolved to balance the
genetic conflict between parents. The paternal imprinted genes
enhance nutrient extraction from the mother and maximize the
growth of the fetus to ensure the survival and development of the
father’s offspring; this is ensured by the imprinting of the IGF-
II gene, with expression of just the paternal allele. In contrast it
is in the interest of the mother to constrain fetal development
and balance nutrient extraction to ensure her own survival
and reproductive competence for future potential offspring,
with potentially different fathers; this is effected by imprinted
expression of the maternal IGF-IIR allele in the mouse, although
this imprinting has not been conserved in humans (36). After
birth the pituitary develops and takes control of the endocrine
system and pituitary GHdrives systemic IGF-I production, which
then plays a more dominant role in growth and development. In
rodents there is a clear switch at weaning when the expression
of IGF-II is virtually ceased and there is an obvious end to the
major systemic role that IGF-II plays. In higher mammals this
switch does not occur and in humans IGF-II is the most prevalent
IGF throughout life. In adult humans there are around 3- to
4-fold higher levels of IGF-II in the circulation, compared to IGF-
I, and there is no abrupt end to the role of IGF-II as clearly
happens in rodents. In rodent models there are therefore two
fundamental differences in the IGF-II system with differences in
the imprinting of the IGF-IIR and a virtual absence of IGF-II in
the circulation of adult rodents but IGF-II remaining the most
abundant of these peptides in adult humans. These experimental
models therefore have limited value in investigating the role
that IGF-II may play in adult cancers in humans. This major
species difference has largely been overlooked in the use of these
experimental models for examining interventions targeting the
IGF-system for treating cancers; many agents worked well in
the rodent models where IGF-I is predominantly the only ligand
but when these were extended into clinical trials in humans the
results have been disappointing (5, 7).
Ever since cancers were likened to embryonic rests or
remnants (37), it has been commented that cancer cells
appear to reactivate a program analogous to that active in
early development. Increased cell proliferation, increased energy
metabolism, evasion of growth suppressors, evasion of contact-
inhibition, evasion of cell death, invasion, metastasis, and
induction of angiogenesis are the hallmarks of cancer, but all
of these processes are also normal and essential requirements
for the development and morphogenesis that occur in early fetal
life when IGF-II is the predominant metabolic regulator. These
properties do not therefore have to be acquired individually by
cancers but if the normal developmental program is reactivated
then they are naturally integrated together. Part of this program,
essential during early development (34), is that these processes
are tightly coordinated according to nutrient availability. That
the organism is in the fed state is signaled to the tissues via
insulin and/or IGFs activating the PI3K pathway, ensuring that
growth and development only proceeds when adequate fuels
are available. As cancer cells reactivate a program analogous to
that active in early development this fundamental control will
also be engaged. In addition, these processes are maintained in
some normal tissues throughout the lifespan: for example, the
constant renewal of epithelial surfaces and the ability of epithelial
surfaces to repair when wounded. Wound healing requires cell
proliferation, migration, inflammation, angiogenesis: indeed it
has been commented that tumors are analogous to wounds that
do not heal (38) or even wounds that over-heal (39).
Nutrition fuels childhood growth but this is context
dependent; if too much energy is expended by physical activity,
maintaining temperature control or by stress, then growth can
be completely arrested. In childhood such contextual changes
permit nutrients/energy to be redirected to muscle for physical
activity or shivering to keep warm or redirected from bone
growth to essential functions such as brain activity and immune
responses etc. Tumors reactivate the same pathways that are
dependent on cues conveying nutrient/energy status, but these
may also be context dependent. Other systemic disturbances such
as insulin-resistance, inflammatory conditions, stress etc. can
result in repartitioning of nutrients/energy that can potentially
benefit the tumor.
During early embryonic development the IGFs,
predominantly IGF-II, not only ensure that growth is co-
ordinated with the availability nutrients and energy, but also
promotes cell migration and invasion. Tissue morphogenesis
requires pluripotent stem cells to differentiate into a variety
of cell types to form a mature tissue and IGF-II maintains
cell survival during these transitions of differentiation; as has
been demonstrated for a number of cell lineages including
the differentiation of myoblasts in skeletal muscle (40). The
IGFs promote and help maintain the rapidly increasing cellular
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heterogeneity during tissue morphogenesis. It is likely that
similar roles are reactivated in tumors. Indeed, this has been
proposed, and some experimental evidence was generated to
support the model, that IGF-II production by some clones
within tumors may help maintain tumor heterogeneity (41). As
extensive tumor heterogeneity has consistently been observed
and is increasingly recognized as contributing to both cancer
progression and failure of treatments, the support of such
heterogeneity may be an important role for IGFs. With multiple
clones it is increasingly likely that one will acquire the properties
required for spread and growth in other tissues and also likely
that some clones will survive therapeutic interventions.
ACQUISITION OF A MALIGNANT
PHENOTYPE
In order to best assess how to reduce the burden of cancer
we need to appreciate the factors contributing to this burden
and how such considerations should be reassessed in light of
the explosion of new findings. Cancer is indeed initiated by
genetic aberrations that result in altered cell behavior leading
to a breakdown in the homeostasis that is normally maintained
by the social network of cells within tissues. This culminates in
antisocial growth and the spread of colonies of cells that can
threaten the viability of the organism. Advances in techniques
for characterizing the genome have revealed the extent of the
considerable genetic damage that accumulates within tumors. It
is also however now evident that considerable genetic alteration
also accumulates in normal tissues where constant cell renewal
occurs and that this is a natural consequence of normal
physiological aging (42–44). Every time that a cell divides
the DNA is not copied with 100% accuracy and with cells
that regularly divide considerable genetic damage accumulates
normally over the years. This has raised the possibility that many,
or even most, of the common age-related epithelial cancers could
occur through this normal physiological process. The increasing
prevalence with age of indolent cancers that can be detected at
autopsy or by screening healthy populations is also consistent
with the primary neoplastic initiation events being frequent
natural occurrences and a consequence of normal aging.
Although cancer cells are considered to behave in a very
abnormal manner: growing, invading and spreading; it has long
been recognized that these are the very same processes that
occur normally during embryonic development and throughout
life in processes such as inflammation and wound healing.
The concept that cancer cells may be embryonic rests was
proposed in the nineteenth century (37). Such concepts have
evolved into the realization that there are patterns of cell
behavior that are programmed within all cells, but which
are normally only expressed during embryogenesis or wound
healing. These same processes can however be inappropriately
reactivated in neoplastic cells, probably either in response to
some form of stress or as the cell slips back down a gradient
of differentiation status (45–47). Embryonic and early life
development have been programmed throughout evolution such
that they are tightly synchronized and tuned to environmental
exposures, especially metabolic conditions. This developmental
programming ensures that the organism learns to adapt to the
nutritional/metabolic environment. This adaptation is conveyed
to the large populations of cells within the organism by
hormones, cytokines, and growth factors: the social signals that
ensure that all cells within tissues act in a unified synchronized
manner. There has been considerable interest that this early
life adaptation has long-term consequences with many lines
of research implicating early-life programming affecting the
development of chronic diseases later in life as originally
proposed by David Barker (48). Cancer cells, as they de-
differentiate, reactivate many of the early life programs and it
is increasingly evident that with this they also acquire similar
cell plasticity and use the same coordinating cues from these
fundamental cell regulators.
CANCER MUTATIONS AND
HETEROGENEITY: A PARADIGM SHIFT
Although cancers arise from genetic damage they clearly do
not arise from a mutation in a single gene or even in a
small number of genes. Uncontrolled cell growth has always
been a threat to complex organisms and, as mutations are an
inevitable natural consequence of cell division, evolution has
crafted many mechanisms to prevent such gene mutations from
directly leading to lethal cancers (49).
Mutations contributing to cancer pathophysiology are termed
driver mutations whereas those not currently known to
contribute are termed passenger mutations. It was originally
thought that for most cancers the initiation and progression
was primarily due to a few common driver mutations but there
is increasing awareness that there are also many additional
plausible driver mutations that occur at low frequency or are
idiosyncratic to an individual clone of cells. The malignant
phenotype is then probably a result of the collaborative effect of
these many mutations that could number many thousands for
any particular tumor.
Gene mutations can occur from exposure to genotoxic
agents, but they also occur naturally due to errors during DNA
replication. Indeed errors in DNA replication occur naturally at
a rate of around one in every 109–1010 nucleotides per cell per
division (50). Throughout life the cells forming the epithelial
surfaces are continuously dividing in order to fulfill their normal
function to replenish the epithelial barriers and this explains why
around 90% of human cancers are carcinomas within epithelial
tissues. In the human colon there are around 1–1.5× 107 crypts,
each maintained by a small population of stem cells and it is
estimated that these stem cells divide every 1–4 days. The rate
at which mutations accumulate over the life-course is then a
relatively simple calculation which indicates that large numbers
of mutations accumulate over the years such that by the age of 70
years, each cell in the normal colon would have acquired between
0.65 and 2.6 mutations per 100,000 bases (51). At the time that
this simple calculation was published actual measurements of the
prevalence of mutations in colorectal tumors had reported rates
of <1 mutation per 100,000 bases (52, 53). In the subsequent
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few years advances in technology have enabled an even more
extensive analysis of the actual mutation prevalence in tumors
according to the age of the patient. Whole exome or whole
genome sequencing data analyzed in tumors from 6,969 patients
with 34 different cancers revealed an increase in mutations with
the age of the patient (54) and with a prevalence that was within
the same range as that calculated for intrinsic mutations in
normal tissues (51). Indeed a few studies have now compared
mutations within tumors and matched non-malignant tissue
from the same individuals and have found the prevalence to be
essentially the same (42–44). It therefore now seems likely that
most of the common epithelial cancers could well be initiated
due to this natural intrinsic mutation rate. Updated modeling
of how epithelial tumors arise suggest that more than half of the
mutations present originated prior to cancer initiation from the
intrinsic natural mutations (55).
In addition to measurements of mutation rates within tumors
such measurements have also been made in normal tissues from
individuals without cancer. A study of mutations in the oncogene
p53 in normal cancer-free adults revealed that cells with mutated
p53 comprised up to 4% of the entire epidermis (56). A more
recent study of the prevalence of mutations in a range of 74
known oncogenic driver genes in normal skin found mutations
in 18–32% of normal skin cells with around 140 driver mutations
per square centimeter and many clones of cells with multiple
oncogenic mutations (57). A similar study of somatic mutations
in normal esophagus from organ donors revealed similar high
prevalence and also showed the age dependent accumulation
of such normal mutations (58). A study of the rate of somatic
mutations at a single gene locus in kidney epithelial cells (again
obtained from organ donors) found a rate of 0.2 mutations
per 100,000 bases in donors from the first decade of life and
this increased with age such that for donors in their eighth
and later decades the rate was 4 mutations per 100,000 bases
(59). Epigenetic and other genetic defects also accumulate with
age (60).
The straightforward mathematics indicates that with around
1013 cells in the body over a lifespan many millions of these
cells will normally acquire sufficient mutations to generate a
malignant genotype. An obvious consequence is then that all
individuals who reach an advanced age will harbor large numbers
of cells with the capacity to initiate a cancer. Thus, although
gene mutations clearly initiate cancers it seems clear from the
recent findings that the cancer causing mutations are not rate-
limiting: in aging individuals there are thousands or millions
of cells with cancer causing mutations and it is the context
that determines whether these cells progress to initiate clinical
cancers. The environment in the tissues within which the cells
reside primarily determines this context.
Well over a century ago Stephen Paget suggested that what
determines where a particular cancer spread within the body
was dependent not only on the disseminated tumor cells, the
“seed,” but also depended on the properties of the tissue where
the secondary metastasis occurs, the “soil” (61). Applying a
similar analogy for when mutated epithelial cells actually develop
into a clinical cancer it would appear that the seeds are not
limited, but are increasingly prevalent with age, and that it is
FIGURE 2 | With aging the epithelial cells that have continuously divided
throughout life naturally accummulate large numbers of mutations and some
of these result in small occult neoplastic lesions, the “seeds.” In normal
individuals such lesions develop slowly and rarely progress to clinical cancer. In
obese individuals the internal milieu, or “soil,” is characterized by high levels of
glucose, insulin, IGFs, inflammatory cytokines and adipokines and this
environment increases the risk that latent neoplastic lesions progress more
rapidly and develop into clinical cancers.
the fertility of “soil” that determines whether these plentiful
“seeds” actually develop into clinically relevant tumors. The
availability of metabolic fuels and the metabolic signals that
regulate this availability are then critically important components
of this environment as they determine the fertility of the “soil”
(Figure 2). That a malignant genotype alone is insufficient to
cause a cancer, but also depends on the context, is supported by
many other lines of evidence that we have reviewed previously
(60). This includes evidence from experimental models in which
the same cells are transplanted into different tissues of an animal
but only form tumors in some of these and also evidence from
human cancers that are caused by somatic mutations that occur
in every cell but which only give rise to cancers in very specific
tissues (60).
One other consequence of the high normal accrual of
mutations that occurs with every cell division is that as
cancers grow and spread they should become more and more
heterogeneous. Indeed, by the time that a human tumor is
clinically apparent or detectable by imaging techniques it has to
be already comprised of millions of cells that would have grown
over many years or decades since initiation and in this time, it
would have accumulated a large number of additional mutations.
The mutational evolution of cancers has been predicted for many
years but with recent advances in sequencing technologies the
actual scale of the heterogeneity has become clear. An early
study with extensive sequencing of multiple biopsies obtained
from four patients with renal carcinomas enabled a phylogenetic
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reconstruction of the evolution of these tumors (62). This study
found many mutations, some of which were shared across
all regions of the primary tumor and metastatic lesions and
obviously occurred before the spread of the cancer to the other
sites, others were shared across the different regions within
the primary but were not present in the metastatic lesions
while others were shared within metastatic lesions but were not
present in the primary and these had presumably occurred after
the spread of metastasis; but there were also many “private”
mutations that were only found at one site either within the
primary or metastatic lesions and had occurred most recently
(62). A phylogenetic reconstruction following the examination
of 21 primary breast tumors concluded that a common ancestor
clone appeared surprisingly early with considerable subsequent
sub-clonal diversification and evolution and that more than
50% of the cancer cells were from a dominant sub-clone that
separated from the most recent common ancestor by many
hundreds or thousands of point mutations (63). The appearance
of this dominant sub-clone appeared to enable growth to the
size that became clinically detectable. Metastatic spread, rather
than the primary tumor, is the cause of more than 90% of cancer
deaths. A recent study examined the phylogenetic evolution of
multiple metastases in 10 men with prostate cancer and found
that in addition to dissemination of cells from the primary tumor,
metastasis to metastasis spread was common and in half of the
cases there was transfer of multiple clones between metastatic
sites (64).
In addition to the genetic heterogeneity there are several other
sources conferring further heterogeneity that can occur even
within genetically identical cells. There has been much interest
in a sub-population of cancer stem cells, tumorigenic cells that
can self-renew; however, there is now considerable evidence
that these stem-like cells form part of a broader phenotypic
plasticity within populations of epithelial cells. Several reports
indicate that not only can stem cells divide asymmetrically to
generate differentiated cells but that differentiated cells can also
de-differentiate to establish new stem cells (65, 66). Indeed there
is evidence that such dynamic interconversions have occurred
within actual clinical tumors (67). The factors governing this
inter-conversion are starting to be elucidated. An examination
of such switching in human melanoma cells implicated the Wnt
and PI3K pathways (68). The stem-like cells are not a distinct cell
type but just one of a number of different stable differentiation
states that cells can switch between. Another important aspect
of this phenotypic plasticity is the inter-conversion termed EMT
and the reverse mesenchymal to epithelial transition (MET). The
most common human cancers are those of epithelial cells that
form the barriers within the body and in which cell divisions
continue throughout life in order to maintain these barriers
but as a consequence also result in an accumulation of genetic
alterations due to the cumulative cell divisions. In order to
function as a barrier the epithelial cells tightly adhere to each
other via adhesion complexes within which E-cadherin plays a
central role. E-cadherin not only serves as an important adhesion
factor but via its interaction with β-catenin acts as a gatekeeper
maintaining the cell differentiation status. Signals such as those
from growth factors, that are often increased in tumors, result in
modifications to the E-cadherin/β-catenin complex destabilizing
adherens junctions and leading to β-catenin translocation to the
nucleus where, with theWnt pathway, it participates in activation
of transcription factors that promote EMT (69, 70). This
phenotypic switch results in loss of the tight cell-cell adhesion
characteristic of epithelial cells and gain of a mesenchymal
phenotype characterized by increased motility and invasiveness;
facilitating the progression to metastatic disease. Accumulating
evidence indicates a role for the insulin/IGF-axis in regulating
EMT (71, 72). In relation to this epithelial plasticity two recent
studies have also both reported that activation of PI3K can
result in de-differentiation of lineage restricted mouse mammary
epithelial cells into multipotent stem-like cells that can then
differentiate into mixed lineage cells resulting in heterogeneity in
subsequent tumors (73, 74).
A further layer of complexity may arise from interactions
between tumor cells and host cells. Cancer cells interact within
tumors with stromal cells, such as fibroblasts and adipocytes,
endothelial cells, and immune cells. In addition to the recent
evidence indicating the normal age-related accumulation of
mutations within rapidly turning-over epithelial cells it has
also become apparent that a normal age-related accumulation
of somatic mutations in hematopoietic stem cells results in
prelavent clonal hematopoiesis in elderly individuals with
mutant clones comprising a large proportion of peripheral
blood cells (75). In addition to potentially being precursors for
hematopoietic cancers; clonal hematopoiesis has been shown to
be a risk factor for age-related atherosclerosis and cardiovascular
disease (76). As the immune system plays an important role
in both the metabolic disturbance associated with increased
adiposity and in policing the spread of neoplastic cells; such
clonal hematopoiesis could have multiple potential effects on the
progression of cancers.
In addition to, or as a consequence of, the genetic and
phenotypic heterogeneity that develops within tumors, as
described above, it is also apparent that metabolic heterogeneity
also develops, even within tumors (77). Glucose is the main
metabolic fuel used in human tissues and Warburg described
the switch in metabolism of glucose to meet the energy
requirements of growing tumors. However, tissues have evolved
a number of different pathways to ensure that essential energy
requirements can be met in a variety of metabolic conditions
and, unsurprisingly, as tumors evolve they also acquire a variety
of mechanisms to maintain their increased energy requirements.
In addition to increased glycolysis they can also utilize oxidative
phosphorylation and use alternative fuels in addition to glucose,
such as glutamine and fatty acids and complex metabolic fluxes
can be established within tumor microenvironments between the
neoplastic cells and stromal cells such as fibroblasts and immune
cells (77). This can greatly complicate the heterogeneity within
tumors and strategies to treat them.
The considerable heterogeneity within tumors and metastatic
lesions has several important consequences. This heterogeneity
provides an explanation for the failure of targeted drugs
that generally have shown great between-patient variability in
therapeutic responses and only short-term survival benefits.
It is unlikely that the same pathways will drive all of the
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heterogeneous clones within a tumor and therefore even if
the dominant clone is successfully targeted, then sub-clones
that are driven by alternate pathways would be relieved of the
competition from the dominant clone and could then soon
regenerate the tumor. This provides an explanation for why most
targeted therapies only work for a limited time, until other clones
enable the tumor to re-grow. In addition, this heterogeneity
will present a considerable challenge to personalized therapy
that is based on the genotype/phenotype analysis of a single
surgical/biopsy sample. The therapeutic challenge presented by
tumor heterogeneity has other implications. In addition to
negative interactions between sub-clones, such as competition
for resources that may lead to a dominant clone; it has also
become increasingly clear that there may be considerable positive
interactions resulting from cooperation between multiple clones,
such as one clone secreting an angiogenic factor that benefits
all clones (78). Interestingly an example of heterogeneous clones
sharing “public goods” has been reported with the expression
of IGF-II from one clone supporting clonal heterogeneity (41).
In addition, the acquisition of drug-resistance associated with
tumor heterogeneity has been reported to involve dynamic
phenotypic switching with cells transiently acquiring drug-
resistance via chromatin-modifications leading to activation of
IGF-I receptor (IGF-IR) signaling (79). Such heterogeneity and
cooperationmay not only favor progression of the primary tumor
and drug resistance but may also facilitate metastasis: a sub-
clone may have the characteristics that confer an advantage in a
secondary site where the ecology may be very different from that
in the primary site.
CANCER CELL METABOLISM
REDISCOVERED
In the early twentieth century the advent ofmodernmedicine was
based on scientific interrogation; during this time observations of
altered cell metabolism in tumors led to this becoming a central
focus of cancer research. In the 1920’s Otto Warburg put forward
a hypothesis to explain the etiology of cancer based on a switch
in cell metabolism that he proposed could be the primary defect;
an effect that has become known as theWarburg effect (80). Even
before this, it was reported that calorie restriction could inhibit
the growth of transplanted tumors in mice (81) and in 1926 it was
observed that excision of spontaneous tumors in fully fed mice
did not prevent the recurrence of cancer in 82% of the animals
but that calorie restriction could reduce the recurrences down
to 27% (82). Observations on the benefits of calorie restriction
subsequently became the most robust intervention for reducing
the growth and progression of a large range of cancers in all
model systems. These seminal observations placed nutrition and
metabolism at the center of cancer research for the first half
of the twentieth century. The explosion in molecular biology
in the latter half of the twentieth century however relegated
altered cell metabolism in tumors to a “Cinderella” status when
center-stage became dominated by the focus on genes. The
promise of genetic discoveries convinced most investigators that
studying the defects in oncogenes and tumor suppressor genes
would yield new therapeutic targets that would revolutionize
cancer treatment. Despite huge advances in understanding, this
paradigm has however largely failed to live up to its early
promise. The lack of impact of the prevailing paradigm on
clinical disease has led to many questioning the need for a
new approach (83, 84). At the same time it has become clear
that the global epidemic in obesity and the associated metabolic
syndrome and type 2 diabetes are having a big clinical impact
on many of the common cancers. This has all contributed to
a “re-discovery” of the important role that metabolism plays
in cancer. The discovery that a number of oncogenes and
tumor-suppressor genes have direct effects on key metabolic
pathways helped propel altered metabolism back into the
mainstream and was then belatedly added to the “hallmarks” of
cancer (85, 86).
Alongside the growing evidence that the obesity epidemic
and associated metabolic disturbances may have a big impact
on the prognosis of many cancers there has also been more
awareness that the widening adoption of a “Western lifestyle”
in Asian and African countries has been accompanied by an
increasing incidence of some of the most common epithelial
cancers. An obvious extrapolation of these observations is that
many of these cancers should be preventable. Many studies have
observed that migrants, from regions of the world where these
cancers are not common, who migrate to Western countries
then rapidly acquire the same high incidence as the indigenous
population (87, 88). In addition, within Eastern countries that
have seen increasing Westernization of diets and lifestyles there
has been a subsequent parallel increase in the incidence of
these cancers (89). This clearly implies that a reversion of these
lifestyle/nutritional effects should provide a means for reducing
the incidence of these cancers. The perception that cancer was
initiated by unavoidable stochastic genetic defects led many to
believe that prevention would be difficult and therefore the
only course would be to treat the clinical disease when it is
detected. However, in most cases the cancer is well advanced
by the stage that it presents clinically. It has been noted that
hoping to cure cancer at an advanced stage is as untenable as
curing advanced polio or curing a person following a severe
stroke (1).
For other widespread chronic diseases, it has long been
widely accepted that prevention would have the greatest impact
at reducing disease burden at the population level and this
has proven the case for cardiovascular and infectious diseases,
but thus far not for cancer. This had much to do with how
the research agenda had evolved differently in the cancer
field, but many have now started to believe that a similar
approach could also be successful for cancer. As the prevailing
paradigm of multi-hit genetic defects offered little prospect for
prevention, this has increased the impetus to explore alternative
concepts such as metabolic perturbations. The growing evidence,
implying an important role for metabolism, and suggesting
that lifestyle alterations may provide a means for prevention
has re-invigorated the interest of public health scientists
and epidemiologists.
There have been many genetic epidemiology studies of the
common cancers; especially Genome-Wide Association Studies
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(GWAS) that have generally failed to live up to early expectations
as there appear to be few common alleles with high penetrance
that contribute to these cancers. This has led to studies of larger
and larger populations to ensure finding many genes that each
had small associations with the cancer (90, 91). At the same
time there have been more traditional epidemiology studies
examining associations with conventional biomarkers; the most
convincing being prospective studies in which biomarkers are
measured in blood samples taken from individuals in large
healthy populations and these measurements then related to the
risk of subsequently developing cancer many years later, thus
limiting the potential for reverse causality. The most robust
observations made across all of the most common epithelial
cancers (breast, prostate, and colorectal) have been associations
with insulin-like growth factors (IGF-I and IGF-II) and insulin
(4, 92–94). These are markers of metabolic status, that depend
on nutrition and lifestyle, implying that they could potentially
serve as intermediate biomarkers to monitor the effectiveness
of nutrition and lifestyle interventions to reduce cancer. As
mediators of interventions that improve metabolic status they
could also help to explain how such interventions may affect the
course of tumorigenesis.
A cancer develops when cells acquire a growth advantage
and lose the normal constraints on growth: cell growth requires
substrates for biosynthesis and an increase use of energy to build
new cells. In normal quiescent cells, that are not proliferating,
metabolism is optimized to extract maximum energy from
metabolic fuels. The most available metabolic substrates in the
body are glucose and glutamine. The maximum generation of
energy from glucose occurs by glycolysis, producing pyruvate
which is then fed into the tricarboxylic acid (TCA) cycle in
the mitochondria where the carbon is eventually burnt down
to carbon dioxide through oxidative phosphorylation. That
this may be different in cancer cells was described early on
by Otto Warburg who observed that this did not happen in
cancer cells but glucose was instead fermented to lactate (80);
a process originally thought to only occur in the absence of
oxygen restricting oxidative phosphorylation. In cancer cells this
however occurs even when adequate oxygen is available and is
referred to as aerobic glycolysis. Although this is very inefficient,
as it yields a fraction of the ATP per molecule of glucose that
could be obtained by mitochondrial oxidation, it was however
realized that in proliferating cells rather than burning all the
carbon down to CO2, the carbon from the glucose was required
for the TCA cycle to provide substrates, such as acetyl-CoA,
to build all of the macromolecules that were needed for cell
duplication. The observed increase in flux through glycolysis
is then required to meet the additional energy requirements.
Following the observation that this occurs in cancers it was
gradually realized that this metabolic switch was a general
requirement for most proliferating cells. The same switch to
aerobic glycolysis occurs during embryonic development and in
cells in normal tissues that continue to proliferate throughout
adult life. The switch to aerobic glycolysis that accompanies cell
proliferation has been observed in lymphocytes during infection
(95, 96) and in epithelia during wound healing (97). It was
subsequently recognized to be a requirement for enterocytes,
lymphocytes, thymocytes, tumor cells, and indeed all rapidly
dividing cells (98).
The insulin/IGF axis evolved to synchronize growth with
nutrient availability and unsurprisingly activation of the pathway
promotes themetabolic switch required in proliferating cells. The
insulin/IGF pathway promotes the Warburg effect by enhancing
glucose uptake and via a variety of additional mechanisms. These
include stimulating aerobic glycolysis via activation of Akt (99),
a switch in the alternative splicing of pyruvate kinase to the
less active isoform PKM2 and promoting nuclear translocation
of PKM2 via activation of the MAP kinase pathway (100).
Promoting the less active PKM2 isoform results in a redirection
of glucose metabolic flux from pure energy generation to more
anabolic processes (101).
SELECTION FOR AUTONOMY
The insulin/IGF/PI3K pathway conveys social signals that
ensure that cell activities are coordinated according to nutrient
availability; if any cells were overactive they may consume
inappropriate amounts of nutrients and compromise the viability
of other cells. In cancers this social “conscience” is lost and the
disease progresses because the tumor develops at the cost of
the organism. It is now clear that most tumors are comprised
of heterogeneous clones of cancer cells and the most successful
clones are those that acquire mutations that convey a selective
advantage. As the signal to go ahead and progress according
to nutrient availability is a limitation for cells that no longer
have concerns for the common good; then acquiring mutations
that lead to intrinsic activation of this pathway, and hence
become independent of the social constraints, would be selected
for as they would confer an advantage. It is now clear that
this indeed occurs and mutations in the gene for the p110
catalytic subunit of PI3K, that free it from the restraints of
p85, resulting in constitutive activation, are extremely common
in a range of human cancers (102, 103). In addition to this,
loss of the counteracting phosphatase PTEN, that normally acts
as a brake on the pathway are even more prevalent in many
common human cancers. Loss of PTEN occurs not just via
inactivating mutations but can also be acquired via a number
of mechanisms including deletions, transcriptional silencing and
protein instability (104). Indeed, loss of PTEN is one of the
most common alterations found in human cancers, second only
to alterations in p53 (105, 106). This not only indicates the
selection advantage, and hence importance, of this pathway to
many common human cancers but it also greatly confounds the
interpretation of studies of the social regulation of this pathway
by insulin/IGFs. Since tumors that have acquired independence
of the external cues via these mechanisms will confound studies
of associations between the levels and activity of insulin/IGFs and
their receptors and they may also confer resistance to therapeutic
strategies to block either the ligands or their receptors. Over
recent years the true extent of intratumoral heterogeneity has
become apparent which further complicates these issues. If just
a minor clone within a tumor has acquired independence of
these external controls; then even if blockade of insulin/IGFs
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were effective for the major clones and initially shrank the
tumor, it could also add a selective advantage to these minor
clones which could then regenerate the tumor. Even an apparent
initial response could then lead to resistance to therapy. The
effectiveness of blockade of the external insulin/IGF signal
would depend on whether acquired constitutive activation of
the internal signaling pathway had occurred. If constitutive
activation of PIK3CA or loss of PTEN occurred early and a
major clone had acquired autonomy, then blocking the external
signal may have little effect; if such an event occurred late
and only minor clones had acquired autonomy then an initial
responsemay be obtained until these clones repopulate the tumor
and then resistance would develop. As most clinical trials are
initiated in patients with advanced disease they will have acquired
considerable heterogeneity and a range of such responses will
occur within different clones.
OBESITY, DIABETES, INSULIN/IGFS, AND
CANCER
Obesity and type II diabetes are the consequence of metabolic
imbalances and lead to perturbed levels of metabolic regulators,
their mediators, and metabolites. These conditions can impact
on the progression of cancers by resetting the context in
which the cancer cells are developing both by altering the
availability of fuels and nutrients and by altered cues and
signals: at least partly mediated by the metabolic regulators.
Obesity and perturbed metabolism are associated with altered
levels of insulin/IGFs, inflammatory cytokines, and important
metabolic fuels. The internal milieu could therefore become
a much more fertile “soil” in which malignant “seeds” could
develop. There are also complex interactions between these
effects: for example, altered availability of lipids and cholesterol
are not only potential fuels for the cancer cells but they are
also substrates for the local production of steroids that may be
important for driving some cancers. In addition, these lipids
are also the major substrates and constituents of membrane
lipid rafts; domains within the cell membrane that contain the
receptors for may signals, including the IR and the IGF-IR, and
changes in the composition of these domains can alter these
essential cell regulators. Insulin resistance results in increased
insulin secretion from the pancreas to try to compensate and
maintain glycemic control. The IGF-system is also reset but in
a more complicated manner due to the differences in its basic
physiology. In terms of circulating levels of IGF-I it is now
clear from large population studies that there is a non-linear
relationship with low IGF-I levels at both low and high BMI
(107–110). Circulating levels of IGF-I increase as BMI increases
from low BMI across the normal range into the over-weight
range, as expected from the nutritional regulation of IGF-I. With
obesity, at higher BMI, however circulating IGF-I levels decrease
as hepatocyte function (the main source of circulating IGF-I) is
compromised. Consistent with this, weight loss in obese subjects
has been reported to result in an increase in circulating IGF-I
levels (111), presumably reflecting an improvement in hepatocyte
function. Some commentators have concluded that the fall in
circulating IGF-I with obesity discounts IGF-I as a major player
in mediating the effects of obesity on cancers (112). This however
assumes that lower circulating levels equates to lower IGF-
activity in the tissues; an assumption that is not sound given
our understanding of IGF-physiology. Most of the circulating
IGF-I is in the ternary complex with IGFBP-3 and the ALS that
is too large to cross capillary barriers. The availability of this to
the tissues then involves complex interactions between IGFBPs,
proteases and the capillary barrier (10). Genetic manipulations
of IGF-I and IGFBP-3 have demonstrated that the biological
activity of IGF-I in the tissues is not directly related to the
circulating concentration in any simple manner (113). Obesity
is also associated with a decrease in pituitary GH secretion
but an increase in the production of IGF-I in response to GH
probably due to the insulin-induced increase in GH-receptors
on hepatocytes (10). With obesity and raised insulin levels there
is also a decrease in IGFBP-1 and IGFBP-2 levels and these
reductions could potentially result in an increase IGF-availability
in tissues (110).
The very indirect relationship between what IGF is active in
a relevant tissue and what can be measured in the circulation
makes it remarkable that associations between circulating IGFs
and cancer have been so consistently observed. It has been
commented that the interpretation of such associations between
IGFs and cancers in epidemiological studies is greater if the
investigators have expertise in the IGF-system than if the
investigators are epidemiologists with no prior expertise in IGF-
physiology (114). This has been suggested to represent bias;
but could just be that those who are knowledgeable of the
complexities of the physiology are more aware of the limitations
of the circulating measurements and may interpret that an
association with such a crude measure of a complex biological
system will probably grossly underestimate its real importance.
Obesity and diabetes are increasing in prevalence at an
alarming rate and it is now clear that they may have a large
impact both on the risk of incidence of a number of cancers
and also in promoting the progression of even more cancers
(115). The evidence that obesity and diabetes are linked to
cancer and the potential causes behind these links has been
reviewed extensively over the last few years (116–118). For some
cancers there are obvious direct links: obesity clearly involves
perturbations in the gastrointestinal system and the main
metabolic tissues and glands and these disturbances may directly
affect the development of cancers in these tissues. Chronic acid
reflux causes damage to the esophagus; gallstones develop in the
gallbladder; the liver is damaged by fatty infiltration; pancreatic
beta-cell failure and fatty infiltration damage the pancreas.
All of these disturbances lead to chronic local inflammation
and increase the risk of cancers in these tissues. Sex steroid
production is altered via many mechanisms; their availability is
increased due to insulin suppression of sex hormone binding
globulin (SHBG) and their metabolism is altered, especially due
to the high aromatase activity in adipose tissue. All of these
contribute to an increase in the risk of cancers that are affected
by sex hormone levels; particularly cancers of the breast and
endometrium and potentially ovary. In addition to these specific
local factors there are clearly systemic factors related to perturbed
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metabolism that alter the environment in which a tumor may
develop. In obesity and diabetes, the availability of metabolites,
especially carbohydrates, fatty acids and lipids, are altered; the
activity of many metabolic regulators is also perturbed, including
insulin and IGFs, and obesity is associated with a chronic
low inflammatory state and the levels of many inflammatory
cytokines are also affected.
Conventional wisdom suggests that obesity and the
development of type 2 diabetes are associated with insulin-
resistance and a compensatory increase in insulin levels could
then stimulate the growth and metabolism of neoplastic cells via
insulin receptors, IR-A or hybrid IGF-I/IR receptors (4, 119).
There have however been many inconsistencies with the popular
concept that dietary calories, and particularly fat intake, are
responsible for obesity; the increasing epidemic has occurred
even in populations were total calories or fat intake has not
increased and attempts to combat the obesity epidemic with
reductions in fat consumption or calorie restriction have
failed to make significant inroads. Reduced calorie intake
increases hunger and reduces energy expenditure which
together lead to weight gain that soon negates any weight loss.
An alternative view that has gained traction is that obesity
is driven by the increasing abundance of foods with high
glycaemic load. Foods such as simple carbohydrates cause
rapid, marked increases in insulin secretion resulting in swift
partitioning of nutrients into adipocytes with a consequent fall
in circulating nutrients which then results in hunger leading to
over-eating (120). This has recently been supported by a large
study using Mendelian randomization in which associations
between natural genetic variants associated with a phenotype
and a given outcome are examined. As genetic variants are
allotted at conception according to Mendel’s second law any
association with an outcome is much less prone to confounding
or reverse-causality; problems that often limit the interpretation
of classical observational association studies. A large population
study found that genetic instruments for insulin secretion
in response to an oral glucose load were strongly associated
with variations in BMI whereas genetic instruments for BMI
were not associated with measured insulin response (121).
This suggests that variations in carbohydrate-induced insulin
secretion drive changes in BMI rather than variations in BMI
driving changes in insulin via insulin-resistance. Although
normal variations in insulin-response appear to drive normal
variations in adiposity: this does not negate the considerable
evidence that clearly shows that increases in adiposity cause
insulin resistance. Obesity may then result from a vicious
cycle in which carbohydrate intake provokes insulin-induced
fuel deposition in adipocytes with the increased adiposity
then leading to insulin resistance and a further compensatory
rise in insulin. The implications of this carbohydrate/insulin
model for obesity on the development of cancers is yet to be
fully elucidated.
Obesity is accompanied by a large number of systemic
changes, in addition to changes in insulin, with increases in
IGF-activity, sex steroids, inflammatory cytokines, adipokines,
angiogenic factors and metabolic fuels, including glucose, fats
and cholesterol. It is clear that all of these factors can affect
the behavior of cancer cells and in reality they probably all
contribute to altering the internal milieu; changing the internal
environment that then affects both the development of the
cancer and its response to therapeutic interventions. In tumors
with considerable heterogeneity these changes in the internal
environment will alter the clonal selection pressures and clones
that can take advantage of the increased supply of energy,
nutrients and stimulants will gain an advantage.
THE NEW GENETIC LANDSCAPE AND THE
RATIONALE FOR A MOVE TO PREVENTION
As described above the last decades have witnessed rapid
advances in technology that have enabled the mapping of the
genetic landscape of cancers in increasingly fine detail. This
has resulted in a growing awareness that the occurrence of
large numbers of mutations and the development of occult
neoplastic lesions are part of the normal aging process in
epithelial tissues. The accumulation of mutations then also
continues after initiation of carcinogenesis and can generate
considerable intra-tumoral heterogeneity. The new awareness
of the etiology of cancers and the problems of targeting
therapy has reinvigorated interest in viewing both the “soil”
and the “seed.” Observations that alterations in the soil affect
the process of carcinogenesis support the proposition that the
occurrence of “seeds” is not rate-limiting. Loss of imprinting
of IGF-II, in which both paternal and maternal alleles are
expressed, increases the risk of developing colorectal cancers
(122) and prostate cancers (123) presumably by setting a more
growth-promoting and hence more fertile “soil.” Indeed, in
a mouse model experimentally induced loss of imprinting of
IGF-II in the prostate promoted widespread neoplasic growths
(124). Similarly, somatic mutations in immune-related genes
can predispose to multiple synchronous genetically distinct
colorectal tumors; presumably due to setting an inflammatory
microenvironment, or “soil,” that favors tumorigenesis and
indicating that the potential “seeds” are naturally present and
abundant (125). Obesity is characterized by a chronic low-
inflammatory state and could also provide such a fertile soil
for tumorigenesis.
The metabolic milieu is one of the most important
components of the soil: setting how fertile the soil is for the
seeds to grow. The metabolic environment of the tumor is
determined by the supply of energy and nutrients and by many
critical metabolic regulators: of which insulin and the IGFs play
a central role. There has been considerable recent progress in
our understanding of how oncogenes, tumor suppressor genes
and malignant transformation results in resetting of tumor cell
metabolism but there is still much to learn regarding how
systemic and local metabolic factors impact on the processes
of tumor progression and metastasis. Population epidemiology
strongly links the clinical prevalence of the common epithelial
cancers to a Western lifestyle. The generally high prevalence
of occult cancers in populations however appears to be similar
in all parts of the world (60); implying that the impact of
a Western lifestyle is not on cancer initiation but affects the
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progression from latent, occult lesions to clinical disease. There
are limitations in interpreting autopsy studies conducted in very
different settings due to large variations in methodology but a
comparison of occult prostate cancers in black American men
with those of white American men by the same pathologists
revealed an identical prevalence (126). In both groups the
prevalence increased with age, exactly in parallel with the increase
in genetic mutations with age (51, 54). The prevalence was
the same in black and white men despite the former having
a 60% higher incidence of clinical prostate cancer and a 2 to
3-fold higher mortality rate (126). This is consistent with the
initiation of tumors being the same in black and white men
but more of these progressing to clinical disease in the black
men. Similarly, a direct comparison between Caucasian and
Asian men revealed a very similar prevalence of occult prostate
cancer despite large disparities in clinical disease (127). The same
conclusion is implied from a meta-analysis of population studies
which indicated that circulating measures of IGF-I were related
to the risk of prostate cancer in studies where the cancers had
been detected as clinically presenting disease but not in studies
where the cancers have been detected by prostate-specific antigen
(PSA) screening (which are mainly low-risk cancers that never
progress to clinical disease) (128). An even stronger association
was observed between IGF-I and mortality from prostate cancer
(129). Together these studies indicate that metabolic status, as
reflected by IGF-I measures, have little effect on the occurrence
of latent, occult lesions, but promote the progression to clinical
cancers. More epidemiology is required with more detailed
phenotypic data in order to better characterize how exposures
affect the different stages of progression rather than just
analyzing incidence.
The accumulating evidence implies that metabolic
derangements associated with a Western lifestyle, and therefore
presumably the metabolic regulators that mediate these effects,
act primarily on progression to clinical disease rather than on
initiation. Metabolic regulators such as insulin and the IGFs
promote the required resetting of cancer cell metabolism and
the initial clonal expansion; but then also help sustain the
de-differentiation and acquisition of clonal heterogeneity that
then favors progression and metastasis. That these fundamental
controls are important for cancer progression is supported by
the prevalence of genetic alterations to the pivotal PI3K/PTEN
signaling pathway that have been observed in tumors across
populations. With the considerable heterogeneity that is now
known to exist within tumors it is highly likely that similar
selection pressure would result in at least some of the many
clones also acquiring such alterations. It should then not be too
surprising that targeting upstream activators of this pathway
showed limited effectiveness when tested in trials in patients
with advanced cancers (5,7) since even if the major clone initially
responds, the presence of minor clones with autonomous
activation of the PI3K pathway could result in ultimate treatment
failure. Following the disappointment with this approach there
has been considerable interest in targeting the primary metabolic
disturbance. There are many effective drugs widely employed
to tackle the diabetes epidemic and there are currently a large
number of trials examining drugs likemetformin against a variety
of different cancers (130, 131). If the same development path is
followed and these are only tested in clinical trials in patients
with advanced disease, who have failed existing treatment
options, then it should not be surprising if progress is limited.
However, as the evidence suggests that the effect of metabolic
milieu is post-initiation, at some stage in the progression to
clinical disease, then this is where these interventions may
provide the most benefit. Clinical trials in cancer patients at
earlier times in the disease pathway are notoriously difficult
for many reasons. Identifying meaningful clinical endpoints is
difficult and there has been considerable reluctance in trialing
potentially toxic new agents when other options may still be
available. The increasing emphasis on prevention rather that
cure however may provide opportunities for new approaches.
This is assuming that it is accepted that prevention means
preventing clinical disease and not preventing initiation: as it is
evident that for many epithelial cancers initiation may occur as
a consequence of normal aging. Drugs such as metformin have
an advantage in such a setting as they have a long track record
and a well-documented safety profile with limited adverse effects
experienced in huge populations treated for metabolic disorders.
This is the most promising setting for examining insulin/IGFs; as
their robust associations with cancer outcomes indicate that they
may be useful intermediate biomarkers. The increased detection
of early cancers in population screening programs may also
generate suitable target groups for such trials. This is already the
case for prostate cancer where increased use of PSA testing has
resulted in the detection of large numbers of early cancers. Many
studies have indicated that the majority of these are indolent
cancers that will not impact on the lifespan of the men (132, 133).
Lifestyle changes or interventions such as metformin, that are
known to do no harm, would be attractive approaches to examine
if they reduce the risk of these indolent cancers progressing
to life-threatening disease. However, very few of these cancers
progress within a reasonable timeframe (134), making trials
with clinical endpoints difficult. Metabolic markers, such as
insulin and IGFs, that have established links with clinical cancers
are currently being employed as intermediate endpoints. This
is supported by the observation that circulating IGF-I levels
were associated with evidence of biochemical progression of
prostate cancer in a large cohort of men followed for 8 years in
an active surveillance program (134). However, eventually hard
clinical outcomes will probably be required in such studies. In
the future similar studies could also be envisaged in colorectal
cancer and breast cancer however these will depend on the
establishment of reliable markers of low-risk disease and markers
of disease progression. Of particular note, the strategy of calorie
restriction that was first observed to restrict the growth of
tumors and their recurrence more than a century ago (81, 82)
has again become a topic of increasing interest. Several different
approaches to calorie restriction are now being investigated
at various stages of the cancer pathway and measures of IGFs
are the most favored intermediate biomarkers to monitor
response (135).
With the realization that by the time that most cancers
are clinically evident the acquired heterogeneity and plasticity
result in immense challenges for attempts to cure advanced
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disease, the emphasis for reducing the burden of cancer will
increasingly shift to strategies for prevention. Concurrently
metabolic imbalance is about to overtake smoking as the
leading preventable cause of cancer and this will be the
main focus of future studies of prevention. Both lifestyle and
pharmaceutical interventions may provide new strategies to slow
the progression ofmost of the common epithelial cancers and this
may enable many individuals being prevented from developing
lethal disease.
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